Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03475173 · ClinicalTrials.gov registry record · NA

New Non-invasive Modalities for Assessing Retinal Structure and Function

A NA study of Hemianopia and Leber Hereditary Optic Neuropathy, sponsored by Randy Kardon.

Recruiting
Registry status
NA
Development phase
500
Enrollment target
1
Study location

NCT03475173 is a NA study of Hemianopia and Leber Hereditary Optic Neuropathy that is actively recruiting participants, run by Randy Kardon. The registered enrollment target is 500 participants, above the 63-participant average among 6 other Hemianopia trials with a reported enrollment target (694% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03475173, a NA study of Hemianopia and Leber Hereditary Optic Neuropathy, is actively recruiting participants, sponsored by Randy Kardon.

RECRUITING
Registry status
NA
Development phase
500 participants
Enrollment target
1
Study location

Study Summary

This study investigates a new technology to assess the structure and function inside the eye. Retinal imaging of subjects with inner and outer retinal defects to detect areas of abnormal structure and function compared to other visual function tests.

Interventions

  • DEVICE LSFG-NAVI

Study Locations (1)

Iowa

  • University of Iowa Department of Ophthalmology - Iowa City

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2019-05-06
Est. Completion 2028-03-01
Phase NA

Sponsor

Randy Kardon

4 total trials

What the Registry Record Tells You About NCT03475173

The ClinicalTrials.gov registry entry for NCT03475173 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 63-participant average among 6 other Hemianopia trials with a reported enrollment target (694% higher). The listed sponsor is Randy Kardon, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Hemianopia appearing as the primary indexed condition, and to 1 intervention - of which LSFG-NAVI is the first listed.

NCT03475173 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.

Frequently Asked Questions

What is clinical trial NCT03475173 about?

NCT03475173 is a clinical study titled "New Non-invasive Modalities for Assessing Retinal Structure and Function". This study investigates a new technology to assess the structure and function inside the eye. Retinal imaging of subjects with inner and outer retinal defects to detect areas of abnormal structure and function compared to other visual function tests.

What is the current status of trial NCT03475173?

This trial is currently recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2019-05-06. Estimated completion is 2028-03-01.

What conditions does trial NCT03475173 study?

This clinical trial studies the following conditions: Hemianopia, Leber Hereditary Optic Neuropathy, Ischemic Optic Neuropathy, Branch Retinal Artery Occlusion, Acute Zonal Occult Outer Retinopathy.

What interventions are being tested in trial NCT03475173?

The interventions under investigation include: LSFG-NAVI (DEVICE).

Who is sponsoring clinical trial NCT03475173?

This trial is sponsored by Randy Kardon, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03475173 being conducted?

This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hemianopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.